Cystic fibrosis and the war for iron at the host-pathogen battlefront

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 6, 2016, Pages 1480-1482

  Bouvier, Nicole M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FLAGELLIN; IRON; PALIVIZUMAB;

ALLELE; ANTIBIOTIC THERAPY; BACTERIAL VIRULENCE; BRONCHOALVEOLAR LAVAGE FLUID; CYSTIC FIBROSIS; DNA MODIFICATION; EPITHELIUM CELL; EVOLUTIONARY ADAPTATION; GENOTYPE; HAEMOPHILUS INFLUENZAE; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IN VITRO STUDY; INFLUENZA VIRUS; INNATE IMMUNITY; LIFE EXPECTANCY; LUNG ALVEOLUS EPITHELIUM; NONHUMAN; NOTE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY VIRUS; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; ANIMAL; BIOFILM; GROWTH, DEVELOPMENT AND AGING; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNITY; NUTRITION; PATHOLOGY; PHYSIOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTION;

ANIMALS; BIOFILMS; HUMANS; IMMUNITY; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84957831378     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1525101113     Document Type: Note

References (23)

1. Cystic Fibrosis Foundation Patient Registry (2015) 2014 Annual Data Report (Cystic Fibrosis Foundation, Bethesda, MD).
2. Brennan ML, Schrijver I (2016) Cystic fibrosis: A review of associated phenotypes, use of molecular diagnostic approaches, genetic characteristics, progress, and dilemmas. J Mol Diagn 18(1): 3-14.
3. Rosenfeld M, Ramsey BW, Gibson RL (2003) Pseudomonas acquisition in young patients with cystic fibrosis: Pathophysiology, diagnosis, and management. Curr Opin Pulm Med 9(6): 492-497.
4. Hendricks MR, et al. (2016) Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity. Proc Natl Acad Sci USA 113: 1642-1647.
5. Stuart B, Lin JH, Mogayzel PJ, Jr, (2010) Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatr Respir Rev 11(3): 177-184.
6. Smith EE, et al. (2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 103(22): 8487-8492.
7. Gnanadhas DP, et al. (2015) Successful treatment of biofilm infections using shock waves combined with antibiotic therapy. Sci Rep 5: 17440.
8. Johansen HK, Høiby N (1992) Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 47(2): 109-111.
9. Petersen NT, et al. (1981) Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma-Possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand 70(5): 623-628.
10. Collinson J, et al. (1996) Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax 51(11): 1115-1122.
11. McCullers JA (2006) Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 19(3): 571-582.
12. Rynda-Apple A, Robinson KM, Alcorn JF (2015) Influenza and bacterial superinfection: Illuminating the immunologic mechanisms of disease. Infect Immun 83(10): 3764-3770.
13. Van Ewijk BE, et al. (2007) RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 61(4): 398-403.
14. de Vrankrijker AM, et al. (2009) Respiratory syncytial virus infection facilitates acute colonization of Pseudomonas aeruginosa in mice. J Med Virol 81(12): 2096-2103.
15. Cassat JE, Skaar EP (2013) Iron in infection and immunity. Cell Host Microbe 13(5): 509-519.
16. Ghio AJ, et al. (2013) Iron accumulates in the lavage and explanted lungs of cystic fibrosis patients. J Cyst Fibros 12(4): 390-398.
17. Moreau-Marquis S, et al. (2008) The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol 295(1): L25-L37.
18. ChinM, et al. (2015) Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations. J Cyst Fibros 14(4): 482-489.
19. Esther CR, Jr, Lin FC, Kerr A, Miller MB, Gilligan PH (2014) Respiratory viruses are associated with common respiratory pathogens in cystic fibrosis. Pediatr Pulmonol 49(9): 926-931.
20. Committee on Infectious Diseases, American Academy of Pediatrics (2015) Respiratory syncytial virus. Red Book: 2015 Report of the Committee on Infectious Diseases, ed Kimberlin DW (American Academy of Pediatrics, Elk Grove Village, IL), 30th Ed.
21. Robinson KA, Odelola OA, Saldanha IJ (2014) Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 5: CD007743.
22. Linnane B, Kiernan MG, O'Connell NH, Kearse L, Dunne CP (2015) Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland. Multidiscip Respir Med 10: 32.
23. ClinicalTrials.gov (2015) A pharmacokinetic and safety study of IV gallium nitrate (ganite) in cystic fibrosis patients (National Library of Medicine, Bethesda, MD). Available at https://clinicaltrials.gov/ct2/show/NCT01093521. Accessed January 13, 2016.